The differential tumor immunotherapeutic effects are attributed to the changes in Th9 cells with Dbp and E2f8 gene knockdown, as analysis of the tumor infiltrated lymphocytes (TIL) reveals no differences between the two groups with respect to other T cell subsets such as Th1, Th2, Th17 or Treg cells. This evidence concerns the gene E2F8 and neoplasm.